title: [A randomized controlled Multi-center clinical trial on mosapride in the treatment of functional dyspepsia].
abstract: OBJECTIVE
  To evaluate the effectiveness and safety of mosapride on treatment of functional dyspepsia.
  
  
  METHODS
  Randomized controlled clinical trial was conducted and patients suffered from functional dyspepsia were included. 5 mg mosapride was given three times daily for 4 weeks in the treatment group. 10 mg domperidone was given three times daily for 4 weeks as control. Changes on symptom score, gastric empty or new occurring events were included as outcomes.
  
  
  RESULTS
  231 patients suffered from functional dyspepsia were selected by inclusion and exclusion criteria from August 15 to Oct 22, 1999. Of these, 108 (46.8%) were males, versus 123 (53.2%) females and 118 (51.2%) in the treatment group and 113 (48.9%) as controls. 222 (96.1%) patients were followed up. Results showed that the total efficacy rates in early satiety and abdominal distension were 84.5% and 90.1% in mosapride after the 2 weeks of treatment. Mosapride seemed to be more effective in improving symptoms of belching and heartburn than that in controls (P < 0.05). In 4 weeks, the total efficacy in improving symptoms of abdominal distention and belching showed more effective in mosapride than that in controls (P < 0.05). Decrease of symptoms score was more in mosapride than that in controls (P < 0.05). Mosapride was less effective in controls in improving the gastric empty in terms of proportion (46.2% vs. 25.9%, P = 0.020) and range (46.2% vs. 24.0%, P = 0.003). Side effects would include diarrhea, constipation, headache, dizziness, insomnia, skin scare and the like. There was no significant difference between the two groups (9.6% in mosapride vs. 14.0% in controls).
  
  
  CONCLUSIONS
  Mosapride was safe and effective in improving the symptoms and gastric empty of functional dyspepsia.
authors.affiliation: Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Shi-yao
authors.initials: SY
authors.lastname: Chen
authors.forename: Ji-yao
authors.initials: JY
authors.lastname: Wang
authors.forename: Chou-wen
authors.initials: CW
authors.lastname: Zhu
authors.forename: Yao-zong
authors.initials: YZ
authors.lastname: Yuan
authors.forename: Bing
authors.initials: B
authors.lastname: Zou
authors.forename: Lu
authors.initials: L
authors.lastname: Xia
authors.forename: Ji-yong
authors.initials: JY
authors.lastname: Liu
authors.forename: Hong-wei
authors.initials: HW
authors.lastname: Xu
authors.forename: Shang-zhong
authors.initials: SZ
authors.lastname: Zhang
authors.forename: Qing
authors.initials: Q
authors.lastname: Wang
authors.forename: Xiang-jun
authors.initials: XJ
authors.lastname: Xie
authors.forename: Zhi-quan
authors.initials: ZQ
authors.lastname: Zhao
authors.forename: Lin
authors.initials: L
authors.lastname: Lin
authors.forename: Nai-zhong
authors.initials: NZ
authors.lastname: Hu
authors.forename: Jian-ming
authors.initials: JM
authors.lastname: Xu
mesh_terms: D000328:Adult; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D005765:Gastrointestinal Agents; D009025:Morpholines; C062720:mosapride